Cover Image
市場調查報告書

視黃酸受體β:開發中產品分析

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 557375
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
視黃酸受體β:開發中產品分析 Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H1 2018
出版日期: 2018年02月13日 內容資訊: 英文 64 Pages
簡介

本報告提供以視黃酸受體β為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

視黃酸受體β;概要

視黃酸受體β;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 3SBio Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Phosphagenics Ltd
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd
  • Valeant Pharmaceuticals International Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1288TDB

Summary

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Retinoic acid receptor beta (RARB) is a nuclear receptor that is encoded by the RARB gene. RARB bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as and regulate activator of gene expression due to weak binding to co-repressors. It is required for skeletal growth, matrix homeostasis and growth plate functions.

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) pipeline Target constitutes close to 16 molecules. Out of which approximately 16 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 6, 4 and 1 respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Immunology, Respiratory, Hematological Disorders, Metabolic Disorders, Oncology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Psoriasis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Breast Cancer, Erythema Multiforme, Hyperlipidemia, Inflammatory Bowel Disease, Myelodysplastic Syndrome, Neutropenia, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Retinopathy Of Prematurity and Type 2 Diabetes.

The latest report Retinoic Acid Receptor Beta - Pipeline Review, H1 2018, outlays comprehensive information on the Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)
  • The report reviews Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Overview
    • Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Lee's Pharmaceutical Holdings Ltd
    • Phosphagenics Ltd
    • Promius Pharma LLC
    • Sol-Gel Technologies Ltd
    • Valeant Pharmaceuticals International Inc
  • Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Drug Profiles
    • (adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (adapalene + clindamycin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (benzoyl peroxide + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (benzoyl peroxide + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (clindamycin phosphate + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AC-261066 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alitretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBD-073 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamibarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPX-6001 + tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Dormant Products
  • Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Discontinued Products
  • Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 22, 2018: Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARa Agonist
      • Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
      • Jan 02, 2018: Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
      • Dec 10, 2017: Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
      • Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris
      • Nov 01, 2017: Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 At ASH Annual Meeting
      • Oct 05, 2017: Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML
      • Sep 29, 2017: Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML
      • Sep 11, 2017: Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients
      • Aug 31, 2017: Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress
      • Aug 21, 2017: Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML
      • Jul 21, 2017: Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients
      • Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris
      • Jun 23, 2017: Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients
      • May 18, 2017: Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by 3SBio Inc, H1 2018
  • Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018
  • Pipeline by Phosphagenics Ltd, H1 2018
  • Pipeline by Promius Pharma LLC, H1 2018
  • Pipeline by Sol-Gel Technologies Ltd, H1 2018
  • Pipeline by Valeant Pharmaceuticals International Inc, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top